Septerna Stock News

SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that Jeffrey Finer, M.D.

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Septerna, Inc. (“Septerna” or the “Company”) (NASDAQ:SEPN) on behalf of Septerna stockholders. Our investigation concerns whether Septerna has violated the federal securities laws and/or engaged in other unlawful business practices.

NEW YORK, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Septerna, Inc. (“Septerna” or the “Company”) (NASDAQ:SEPN). The investigation concerns whether Septerna and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.

Investors can contact the law firm at no cost to learn more about recovering their losses Investors can contact the law firm at no cost to learn more about recovering their losses

Septerna (NASDAQ:SEPN) shares tumbled more than 60% after the clinical-stage biotechnology firm announced it is halting its Phase 1 clinical trial of SEP-786 targeting hypoparathyroidism. The company said it chose to discontinue the trial due to the occurrence of elevated bilirubin levels in trial participants.

PHILADELPHIA, PA / ACCESS Newswire / February 18, 2025 / Kehoe Law Firm, P.C. is investigating securities claims on behalf of investors of Septerna, Inc. ("Septerna" or the "Company") (NASDAQ:SEPN).

Trial decision follows unanticipated events of elevated unconjugated bilirubin levels Company advancing multiple next-generation PTH1R agonists with distinct and unrelated chemical structures relative to SEP-786 SOUTH SAN FRANCISCO, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of GPCR drug discovery, today a...

SOUTH SAN FRANCISCO, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Septerna, a clinical-stage biotechnology company pioneering a new era of GPCR-targeted drug discovery, today announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 3:45 p.m. PT in San Francisco.